Sponsor Check › Issuer
Corporation · organized in ONTARIO, CANADA · formed more than five years before filing · TORONTO, Ontario, Canada (as filed: A6) · SEC CIK 1621394
Data last updated: Oct 23, 2026, 5:45 PM ET · Latest filing by this issuer: Apr 12, 2019 · Courts (RECAP) last checked: Oct 23, 2026, 11:54 PM ET · SEC enforcement last checked: not yet
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:54 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
No SEC search has run yet for this issuer.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:54 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
No public statement by this issuer has been collected yet, so there is nothing to compare. Sources compared: the sponsor's own website (known from the issuer's own filings — Form C issuer website, EDGAR company profile — an approved profile claim or Form ADV Item 1.I of its matched adviser) · SEC Form D · SEC Form ADV (IAPD) · Internet Archive · No website is on file for this issuer yet.
0 of 9 offerings report sales commissions; 0 report finder's fees; 0 report proceeds to related persons.
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Apr 12, 2019 D File 021-337142 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 13, 2018 D File 021-327782 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 17, 2017 D File 021-290894 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 6, 2017 D File 021-277773 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 7, 2016 D/A File 021-272031 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 25, 2016 D File 021-258113 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 24, 2015 D File 021-253831 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jun 17, 2015 D File 021-241980 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 5, 2014 D File 021-229547 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
0 recorded documents and 0 ownership records matched to Synaptive Medical Inc. in the sources searched.
Not found in sources searched as of Oct 23, 2026, 8:59 PM ET: Hillsborough County FL Clerk of Court Official Records daily index (publicrec.hillsclerk.com D/P/M files), 2 daily files (Oct 14, 2026 to Oct 15, 2026) — loaded Oct 23, 2026, 8:59 PM ET; Florida DOR NAL roll (Hillsborough 39) roll year 2026 — loaded Oct 23, 2026, 8:54 PM ET; Florida DOR NAL roll (Dade 23) roll year 2026 — loaded Oct 23, 2026, 8:58 PM ET; Harris County Appraisal District real_acct.txt roll year 2026 — loaded Oct 23, 2026, 8:58 PM ET; Dallas Central Appraisal District ACCOUNT_INFO.CSV roll year 2026 — loaded Oct 23, 2026, 8:58 PM ET. Not yet searched for this issuer (queued): NYC ACRIS via NYC Open Data (Real Property Parties 636b-3b5g, Master bnx9-e6tj, Legals 8h5j-fqxa, Document Control Codes 7isb-wh4c) · NYC PLUTO ownership via NYC Open Data (64uk-42ks) · Cook County IL Assessor via Cook County Open Data (Parcel Sales wvhk-k5uv; Parcel Addresses 3723-97qp). Records in other counties, and recorder indexes we do not yet cover, were not searched.
Property records coverage: New York City (ACRIS recorded documents and PLUTO ownership, looked up per issuer when its page is viewed; re-checked when the page is viewed again more than 30 days after the last check); Hillsborough County FL (recorded documents from Oct 14, 2026 forward; ownership from FL DOR roll 2026); Cook County IL (assessor ownership and deed/sale records, looked up per issuer when its page is viewed); Harris County TX and Dallas County TX (assessor ownership rolls only, 2026 roll; no deed, mortgage or sale records); Miami-Dade County FL (ownership from FL DOR roll only; Clerk recorded documents not yet searched). Recorder indexes for TX, AZ, IL and WA counties, mortgages and liens outside NYC and FL, lis pendens and foreclosure notices everywhere, Miami-Dade County FL recorded documents, Maricopa County AZ, King County WA, Salt Lake County UT, and all other counties are not yet searched. Last refresh by source: Hillsborough County FL Clerk daily index Oct 23, 2026, 8:59 PM ET; Dallas Central Appraisal District ACCOUNT_INFO.CSV Oct 23, 2026, 8:58 PM ET; Harris County Appraisal District real_acct.txt Oct 23, 2026, 8:58 PM ET; Florida DOR NAL roll (Dade 23) Oct 23, 2026, 8:58 PM ET; Florida DOR NAL roll (Hillsborough 39) Oct 23, 2026, 8:54 PM ET. NYC and Cook County are looked up per issuer when its page is viewed; the most recent such lookup on this site finished Oct 24, 2026, 2:12 AM ET. Parties are named as the recorder's index names them (role suffixes as recorded); no address, account number or trust date is shown for an individual, and individual owners of record (home ownership) are not matched or shown. Items still in human review are not shown.
Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.
| File no. | Original Form D | Latest filing | Amendments | Offered (latest) | Sold (latest) | Industry (latest) |
|---|---|---|---|---|---|---|
| 021-337142 | Apr 12, 2019 EDGAR ↗ | Apr 12, 2019 D EDGAR ↗ | 0 | $4,993,688 | $4,993,688 | Other Health Care |
| 021-327782 | Dec 13, 2018 EDGAR ↗ | Dec 13, 2018 D EDGAR ↗ | 0 | $5,006,312 | $5,006,312 | Other Health Care |
| 021-290894 | Jul 17, 2017 EDGAR ↗ | Jul 17, 2017 D EDGAR ↗ | 0 | $14,218,191 | $14,218,191 | Biotechnology |
| 021-277773 | Jan 6, 2017 EDGAR ↗ | Jan 6, 2017 D EDGAR ↗ | 0 | $901,256 | $901,256 | Biotechnology |
| 021-272031 | Oct 7, 2016 EDGAR ↗ | Oct 7, 2016 D/A EDGAR ↗ | 1 latest Oct 7, 2016 | $3,725,536 | $3,725,536 | Biotechnology |
| 021-258113 | Feb 25, 2016 EDGAR ↗ | Feb 25, 2016 D EDGAR ↗ | 0 | $910,741 | $910,741 | Biotechnology |
| 021-253831 | Dec 24, 2015 EDGAR ↗ | Dec 24, 2015 D EDGAR ↗ | 0 | $2,089,857 | $2,089,857 | Biotechnology |
| 021-241980 | Jun 17, 2015 EDGAR ↗ | Jun 17, 2015 D EDGAR ↗ | 0 | $2,101,853 | $2,101,853 | Biotechnology |
| 021-229547 | Dec 5, 2014 EDGAR ↗ | Dec 5, 2014 D EDGAR ↗ | 0 | $887,083 | $887,083 | Biotechnology |
Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.
| Filing | Form D filed Apr 12, 2019 SEC file no. 021-337142 · accession 0001621394-19-000001 |
|---|---|
| Raise progress | $4,993,688 sold of $4,993,688 offered (100%) · $0 remaining · first sale Mar 26, 2019 |
| Filing timing | Date of first sale: Mar 26, 2019 · Form D filed: Apr 12, 2019 (17 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 2,769 days (7.6 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 1 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Debt; Option, warrant or other right to acquire |
| Entity details | Organized in ONTARIO, CANADA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Other Health Care |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Peter Wehrly, Director (Apr 11, 2019) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$54,310. Offering size: $4,993,688. Typical range: $829,831–$9,999,998. Investors: 1. Typical range: 2–15. "Similar" = Other Health Care, Rule 506(b). Based on 4,189 Form D filings 2021–2026 in the same industry and exemption (Other Health Care, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 1,330, offering size 3,970, investors 3,669. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Dec 13, 2018 SEC file no. 021-327782 · accession 0001621394-18-000001 |
|---|---|
| Raise progress | $5,006,312 sold of $5,006,312 offered (100%) · $0 remaining · first sale Nov 28, 2018 |
| Filing timing | Date of first sale: Nov 28, 2018 · Form D filed: Dec 13, 2018 (15 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 2,887 days (7.9 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 1 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Debt; Option, warrant or other right to acquire |
| Entity details | Organized in ONTARIO, CANADA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Other Health Care |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Peter Wehrly, Director (Dec 12, 2018) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$54,310. Offering size: $5,006,312. Typical range: $829,831–$9,999,998. Investors: 1. Typical range: 2–15. "Similar" = Other Health Care, Rule 506(b). Based on 4,189 Form D filings 2021–2026 in the same industry and exemption (Other Health Care, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 1,330, offering size 3,970, investors 3,669. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Jul 17, 2017 SEC file no. 021-290894 · accession 0001621394-17-000003 |
|---|---|
| Raise progress | $14,218,191 sold of $14,218,191 offered (100%) · $0 remaining · first sale Jun 30, 2017 |
| Filing timing | Date of first sale: Jun 30, 2017 · Form D filed: Jul 17, 2017 (17 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 3,403 days (9.3 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 18 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity; Option, warrant or other right to acquire |
| Entity details | Organized in ONTARIO, CANADA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Cameron Piron, President (Jul 17, 2017) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $14,218,191. Typical range: $2,000,000–$19,999,994. Investors: 18. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Jan 6, 2017 SEC file no. 021-277773 · accession 0001621394-17-000002 |
|---|---|
| Raise progress | $901,256 sold of $901,256 offered (100%) · $0 remaining · first sale Dec 23, 2016 Issuer's note: Conversions have been made form Canadian dollars to US dollars using an estimated $CAD1.3535/$USD1.00 exchange rate, as of close of business on December 23, 2016. |
| Filing timing | Date of first sale: Dec 23, 2016 · Form D filed: Jan 6, 2017 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 3,592 days (9.8 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 6 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in ONTARIO, CANADA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Peter Dans, CFO (Jan 5, 2017) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $901,256. Typical range: $2,000,000–$19,999,994. Investors: 6. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D/A (amendment) filed Oct 7, 2016 · amends 0001621394-16-000004 ↗ SEC file no. 021-272031 · accession 0001621394-16-000005 · filing 2 of 2 in this offering |
|---|---|
| Raise progress | $3,725,536 sold of $3,725,536 offered (100%) · $0 remaining · first sale Sep 24, 2016 Issuer's note: Conversions have been made from Canadian dollars to US dollars using an estimated $CAD 1.3171/$USD 1.00 exchange rate, as of close of business on September 23, 2016. |
| Filing timing | Date of first sale: Sep 24, 2016 · Original Form D filed: Oct 7, 2016 (13 days after first sale) · This amendment (Form D/A) filed: Oct 7, 2016 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
| Time since first sale | 3,682 days (10.1 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Oct 7, 2016. Most recent amendment for this offering in our index: this filing, Oct 7, 2016. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 18 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in ONTARIO, CANADA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Cameron Piron, President (Oct 7, 2016) |
| Changes vs previous filing |
Compared with the D filed Oct 7, 2016 (EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $3,725,536. Typical range: $2,000,000–$19,999,994. Investors: 18. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Oct 7, 2016 SEC file no. 021-272031 · accession 0001621394-16-000004 · filing 1 of 2 in this offering |
|---|---|
| Raise progress | $3,428,905 sold of $3,428,905 offered (100%) · $0 remaining · first sale Sep 24, 2016 Issuer's note: Conversions have been made from Canadian dollars to US dollars using an estimated $CAD 1.3171/$USD 1.00 exchange rate, as of close of business on September 23, 2016. |
| Filing timing | Date of first sale: Sep 24, 2016 · Form D filed: Oct 7, 2016 (13 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 3,682 days (10.1 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Oct 7, 2016 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 18 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in ONTARIO, CANADA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Cameron Piron, President (Oct 7, 2016) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $3,428,905. Typical range: $2,000,000–$19,999,994. Investors: 18. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Feb 25, 2016 SEC file no. 021-258113 · accession 0001621394-16-000003 |
|---|---|
| Raise progress | $910,741 sold of $910,741 offered (100%) · $0 remaining · first sale Feb 12, 2016 |
| Filing timing | Date of first sale: Feb 12, 2016 · Form D filed: Feb 25, 2016 (13 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 3,907 days (10.7 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 6 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in ONTARIO, CANADA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Gal Sela, Secretary & Director (Feb 25, 2016) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $910,741. Typical range: $2,000,000–$19,999,994. Investors: 6. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Dec 24, 2015 SEC file no. 021-253831 · accession 0001621394-15-000002 |
|---|---|
| Raise progress | $2,089,857 sold of $2,089,857 offered (100%) · $0 remaining · first sale Dec 15, 2015 |
| Filing timing | Date of first sale: Dec 15, 2015 · Form D filed: Dec 24, 2015 (9 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 3,966 days (10.9 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 14 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in ONTARIO, CANADA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Cameron Piron, President (Dec 23, 2015) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $2,089,857. Typical range: $2,000,000–$19,999,994. Investors: 14. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Jun 17, 2015 SEC file no. 021-241980 · accession 0001621394-15-000001 |
|---|---|
| Raise progress | $2,101,853 sold of $2,101,853 offered (100%) · $0 remaining · first sale Jun 5, 2015 |
| Filing timing | Date of first sale: Jun 5, 2015 · Form D filed: Jun 17, 2015 (12 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 4,159 days (11.4 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 26 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in ONTARIO, CANADA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Cameron Piron, President (Jun 17, 2015) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $2,101,853. Typical range: $2,000,000–$19,999,994. Investors: 26. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Filing | Form D filed Dec 5, 2014 SEC file no. 021-229547 · accession 0001621394-14-000001 |
|---|---|
| Raise progress | $887,083 sold of $887,083 offered (100%) · $0 remaining · first sale Nov 21, 2014 |
| Filing timing | Date of first sale: Nov 21, 2014 · Form D filed: Dec 5, 2014 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
| Time since first sale | 4,355 days (11.9 years) |
| Annual amendments | Issuer reported the offering is not expected to last more than one year. No amendment for this offering in our index (filings 2008 → Oct 22, 2026; checked Oct 23, 2026, 5:45 PM ET). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
| Investors | 6 total · issuer reported no non-accredited investors |
| Exemption claimed | Rule 506(b) — no general advertising; up to 35 non-accredited investors allowed |
| Minimum investment accepted | $0 as filed (no minimum reported) |
| Securities offered | Equity |
| Entity details | Organized in ONTARIO, CANADA · formed more than five years before filing · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
| Industry | Biotechnology |
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
| Signed by | Gal Sela, Secretary and Director (Dec 5, 2014) |
| Market context | Minimum investment: $0 as filed (no minimum reported). Typical range for similar offerings: $10,000–$50,000. Offering size: $887,083. Typical range: $2,000,000–$19,999,994. Investors: 6. Typical range: 2–16. "Similar" = Biotechnology, Rule 506(b). Based on 3,253 Form D filings 2021–2026 in the same industry and exemption (Biotechnology, Rule 506(b); original Form D notices, one per offering) (Form D data, SEC). Ranges are the middle half (25th–75th percentile) of the filings that reported each value: minimum investment 704, offering size 3,078, investors 3,148. Computed by PartnerFacts as of Oct 23, 2026, 5:45 PM ET. No ranking or score. Source: PartnerFacts data & coverage. |
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
| Amendment filed | File no. | Compared with | What changed (both values as filed) |
|---|---|---|---|
| Oct 7, 2016 EDGAR ↗ | 021-272031 | Oct 7, 2016 D | total sold: $3,428,905 (Oct 7, 2016) → $3,725,536 (Oct 7, 2016) · total offering: $3,428,905 (Oct 7, 2016) → $3,725,536 (Oct 7, 2016) · related persons added (Oct 7, 2016): William Patrick Ryan, James L. Cloar, Peter Dans |
Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Values as filed; no conclusion is drawn.
All Form D filings for this CIK on SEC EDGAR ↗. History: 0 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Apr 12, 2019. Industry as reported, by offering: Previous offerings: Biotechnology (2014–2017). Latest offering: Other Health Care (2018–2019; most recent Apr 12, 2019).
| Name | Relationship | Address state | On filings (first → last) | Also listed on |
|---|---|---|---|---|
| Andrew Prozes | Director | Ontario, Canada (as filed: A6) | Dec 24, 2015 → Apr 12, 2019 on 8 of 10 filings listed on the latest filing | — |
| Cameron Piron | Executive Officer, Director | Ontario, Canada (as filed: A6) | Dec 5, 2014 → Apr 12, 2019 on 10 of 10 filings listed on the latest filing | — |
| David Caluori | Director | Ontario, Canada (as filed: A6) | Jan 6, 2017 → Apr 12, 2019 on 4 of 10 filings listed on the latest filing | — |
| David Bruce Gallop also filed as David Gallop | Executive Officer, Director | Ontario, Canada (as filed: A6) | Dec 5, 2014 → Apr 12, 2019 on 10 of 10 filings listed on the latest filing | — |
| Douglas Glen Janzen | Director | Ontario, Canada (as filed: A6) | Jul 17, 2017 → Apr 12, 2019 on 3 of 10 filings listed on the latest filing | 1 other issuer |
| Glenn Daniel Steele Jr. | Director | Ontario, Canada (as filed: A6) | Jul 17, 2017 → Apr 12, 2019 on 3 of 10 filings listed on the latest filing | — |
| Peter Lee Wehrly also filed as Peter Wehrly | Director, Executive Officer | Ontario, Canada (as filed: A6) | Jan 6, 2017 → Apr 12, 2019 on 4 of 10 filings listed on the latest filing | — |
| Sandra Clarke | Executive Officer | Ontario, Canada (as filed: A6) | Apr 12, 2019 on 1 of 10 filings listed on the latest filing | — |
| Wesley Hodges | Executive Officer, Director | Ontario, Canada (as filed: A6) | Dec 5, 2014 → Apr 12, 2019 on 10 of 10 filings listed on the latest filing | — |
| George Peter Dans | Executive Officer | Ontario, Canada (as filed: A6) | Jul 17, 2017 → Dec 13, 2018 on 2 of 10 filings not listed on the latest filing (Apr 12, 2019) | — |
| Michael DeMane | Director | Ontario, Canada (as filed: A6) | Jul 17, 2017 on 1 of 10 filings not listed on the latest filing (Apr 12, 2019) | — |
| Richard Butland | Director | Ontario, Canada (as filed: A6) | Jan 6, 2017 → Jul 17, 2017 on 2 of 10 filings not listed on the latest filing (Apr 12, 2019) | — |
| Vincent Luciani | Executive Officer | Ontario, Canada (as filed: A6) | Jul 17, 2017 on 1 of 10 filings not listed on the latest filing (Apr 12, 2019) | — |
| William Patrick Ryan | Executive Officer | Ontario, Canada (as filed: A6) | Oct 7, 2016 → Jul 17, 2017 on 3 of 10 filings not listed on the latest filing (Apr 12, 2019) | — |
| Doug Janzen | Director | Ontario, Canada (as filed: A6) | Jun 17, 2015 → Jan 6, 2017 on 6 of 10 filings not listed on the latest filing (Apr 12, 2019) | — |
| Gal Sela | Executive Officer, Director | Ontario, Canada (as filed: A6) | Dec 5, 2014 → Jan 6, 2017 on 7 of 10 filings not listed on the latest filing (Apr 12, 2019) | — |
| James Cloar also filed as James L. Cloar | Executive Officer | Ontario, Canada (as filed: A6) | Oct 7, 2016 → Jan 6, 2017 on 2 of 10 filings not listed on the latest filing (Apr 12, 2019) | — |
| Peter Dans | Executive Officer | Ontario, Canada (as filed: A6) | Oct 7, 2016 → Jan 6, 2017 on 2 of 10 filings not listed on the latest filing (Apr 12, 2019) | — |
Executive officers, directors and promoters as self-reported by the issuer, one row per person. Spellings of the same name (same first and last name, or the same full name that EDGAR split differently into middle and last name) with no conflicting middle initial are shown on one row (none on this issuer); dates and counts come from the filings that list each name. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗. Middle names: the SEC Form D data set (RELATEDPERSONS.tsv) repeats the previous person's middle name into later rows of the same filing; where that happened PartnerFacts shows the name without the repeated middle name and keeps the data-set spelling on record (Andrew Glen Prozes; David Patrick Caluori; David Peter Caluori; David Glen Caluori; Peter Patrick Wehrly; Sandra Glen Clarke; Richard Patrick Butland; Richard Lee Butland; Vincent Patrick Luciani; James Patrick Cloar) — the filing on EDGAR is the source.
Other issuers listing the same people:
Shared address: this business address appears on filings for 2 other issuers. Stated as a count only (suite numbers ignored) — many addresses are shared office buildings or registered agents. As of Oct 23, 2026, 5:45 PM ET.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Not yet searched. Sources to be searched: SEC Investment Adviser Information Reports — Form ADV data for SEC-registered advisers and exempt reporting advisers (file dated 2026-10-02); SEC Investment Adviser Public Disclosure (IAPD) firm search — registered and exempt reporting advisers · Search queued. Results are added automatically; check back later.
Not yet searched.
Sources to be searched: the sponsor's website (none on record yet; a sponsor's website is known only from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim or Form ADV Item 1.I of its matched adviser — we never look it up elsewhere) for Meta Pixel ids and Facebook / Instagram page links; Meta Ad Library API: not yet searched (API access pending). We never read facebook.com or instagram.com; readers get a link to Meta's public Ad Library instead.
Not found in sources searched.
Sources searched for a website: Form C data set (issuer websites as filed), Form ADV data set (Item 1.I of matched advisers) — as of Oct 23, 2026, 11:20 PM ET: none on file for this issuer. The sponsor website, the Internet Archive and GDELT news index are read only once a site is on file; a sponsor's website is known only from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim or Form ADV Item 1.I of its matched adviser — we never look it up elsewhere. We never collect personal or family accounts.
Entity standing: not checked (no official programmatic source for issuers located outside the US (business address code as filed: A6; jurisdiction of organization as filed: ONTARIO, CANADA) yet).
Export this report as PDF (all source links + data timestamp; members · included free during the launch period) · Premium
Request diligence pack (Premium) PartnerFacts asks the sponsor for the standard information pack and delivers it to you labelled "provided by the sponsor".
No corrections have been requested for this page.
Filing-to-filing changes are in Amendment history above.
The complete public-record profile for Synaptive Medical Inc., plus the weekly new-filings list.
Only "Connect me" shares your details — with this sponsor, at a flat price we charge them, never tied to whether you invest. "Just researching" shares nothing.
Free. Tell us what's wrong and, if you can, where the correct public record is. Every request is logged with its status (received → under review → fixed / confirmed with source).
Sponsors may add a sourced explanation next to any fact on this page. Reviewed before publishing; never edits the public record.
Free. Get the "Claimed by sponsor" chip and a confirmed contact for corrections. Claiming never changes the public-record section.